Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
暂无分享，去创建一个
C. Brink | M. Josipovic | G. Persson | O. Hansen | W. Ottosson | D. Møller | A. Khalil | M. Knap | L. Hoffmann | A. Appelt | T. Nielsen | P. Sibolt | T. Schytte | C. M. Lutz | C. Nyhus | S. Borissova | Mikkel Drøgemüller Lund